drugset / Trial / NCT07284576

Ultralow Dose PET Imaging of 18F-flurpiridaz

NCT07284576 ↗

Phase 2 Enrolling by invitation 200 enrolled Akiva Mintz
NaSingle-groupOpen-labelDiagnostic

Summary

The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for known or suspected coronary artery disease (for detecting myocardial ischemia or infarction) detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-flurpiridaz and be imaged on a new type of high sensitivity PET scanner for up to 3 hours

Timeline

Start
2025-12-16
Primary completion
2030-06-30
Completion
2030-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-flurpiridaz Diagnostic / imaging agent 0.25 unknown Other